Key highlights
- Zenyaku Kogyo and Chugai terminate co-promotion of Rituxan (rituximab) IV 100 mg and 500 mg effective September 3, 2026.
- Chugai will cease sales upon sell-out of its remaining inventory.
- From September 4, 2026 Zenyaku Kogyo will assume sole responsibility for sales and medical information for Rituxan.
- Both companies will coordinate the transition to maintain a stable supply and ensure appropriate use.
Overview
Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. will terminate co-promotion in Japan for Rituxan intravenous infusion (rituximab) 100 mg and 500 mg; the co-promotion ends effective September 3, 2026.
Timing and responsibilities
Chugai will end sales upon sell-out of its remaining inventory and, effective September 4, 2026, Zenyaku Kogyo will assume sole responsibility for sales and the provision of medical information for Rituxan.
Transition and supply
Both companies will coordinate the transfer of sales activities during the transition period and continue efforts to maintain a stable supply, provide medically aligned information, and promote appropriate use.
